Study explores the potential to repurpose neuroactive drugs, originally approved for neurological disorders, for the ...

Hudson Therapeutics, a leading innovator in therapeutic solutions and a US subsidiary of Shaperon, announced Shaperon’s entry ...

Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in ...

The study commencement is based on previous clinical safety and efficacy data, along with robust preclinical evidence.

AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease Prescreening rate of Phase 2b ReTain trial triggers clinical ...

Results from a preclinical study in mice and a collaborative clinical study in patients show that the type 2 immune response -- associated with parasitic infection and thought to play a negative role ...

AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease Prescreening rate of Phase 2b ReTain trial triggers ...

NEW YORK – After the successful completion of its preclinical trial, Accelerate Diagnostics is preparing to submit its new Wave antimicrobial susceptibility testing platform to the US Food and Drug ...

The trial results indicated minimal adverse events and no evidence of immune-mediated clearance following TX45 treatment.

(Janssen), a Johnson & Johnson company. The milestone payment has been triggered by the rapid rate of prescreening in the potentially registrational Phase 2b ReTain trial investigating ...